Tcr2 Therapeutics (TCRR) Lifted to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Tcr2 Therapeutics (NASDAQ:TCRR) from a sell rating to a hold rating in a report issued on Tuesday morning, Zacks.com reports.

According to Zacks, “TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing T cell therapies for patients suffering from cancer. Its product candidate includes TC-210, TC-220, TC-410, TC-110 and TC-310 which are in clinical stage. TCR2 Therapeutics Inc. is based in Cambridge, Massachusetts. “

TCRR has been the subject of a number of other research reports. BMO Capital Markets initiated coverage on shares of Tcr2 Therapeutics in a research report on Monday, March 11th. They set an outperform rating and a $37.00 price target for the company. Wedbush assumed coverage on shares of Tcr2 Therapeutics in a research report on Monday, March 11th. They set an outperform rating and a $28.00 price target for the company. They noted that the move was a valuation call. Svb Leerink assumed coverage on shares of Tcr2 Therapeutics in a report on Monday, March 11th. They issued an outperform rating and a $27.00 price objective for the company. Jefferies Financial Group assumed coverage on shares of Tcr2 Therapeutics in a report on Monday, March 11th. They issued a buy rating and a $31.00 price objective for the company. Finally, Leerink Swann assumed coverage on shares of Tcr2 Therapeutics in a report on Monday, March 11th. They issued an outperform rating for the company. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Tcr2 Therapeutics has a consensus rating of Buy and a consensus target price of $30.75.

TCRR stock opened at $14.08 on Tuesday. Tcr2 Therapeutics has a twelve month low of $13.31 and a twelve month high of $25.47. The company has a market cap of $340.67 million and a PE ratio of -0.14.

Tcr2 Therapeutics (NASDAQ:TCRR) last released its quarterly earnings results on Monday, May 13th. The company reported ($4.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($4.47). Research analysts expect that Tcr2 Therapeutics will post -6.08 EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the business. MPM Asset Management LLC bought a new stake in Tcr2 Therapeutics in the first quarter valued at $67,192,000. Redmile Group LLC bought a new stake in Tcr2 Therapeutics in the first quarter valued at $28,686,000. ArrowMark Colorado Holdings LLC bought a new stake in Tcr2 Therapeutics in the first quarter valued at $8,204,000. Hillhouse Capital Management LTD. bought a new stake in Tcr2 Therapeutics in the first quarter valued at $5,628,000. Finally, JPMorgan Chase & Co. bought a new stake in Tcr2 Therapeutics in the first quarter valued at $3,463,000. 20.43% of the stock is owned by hedge funds and other institutional investors.

Tcr2 Therapeutics Company Profile

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.

Read More: What is a support level?

Get a free copy of the Zacks research report on Tcr2 Therapeutics (TCRR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Tcr2 Therapeutics (NASDAQ:TCRR)

Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.